Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy
Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...
J&J
EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma
The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson...
J&J’s Rybrevant Secures Full FDA Approval for NSCLC with EGFR Exon 20 Insertions
The US Food and Drug Administration (FDA) has granted Johnson & Johnson (J&J; NYSE: JNJ)...
Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC
South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...
FDA Authorizes Biweekly Dosing for J&J’s Tecvayli in Multiple Myeloma Treatment
The US Food and Drug Administration (FDA) has granted authorization for a biweekly dosing regimen...
LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend
LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...
Johnson & Johnson’s Talquetamab and Daiichi Sankyo’s Enhertu Eye Priority Review in China
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J, NYSE:...
Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China
Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent...
Johnson & Johnson’s Rybrevant and Lazertinib Filings Accepted for Review by CDE
The Center for Drug Evaluation (CDE) has confirmed that Johnson & Johnson’s (J&J, NYSE: JNJ)...
J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth
Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for...
J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...
Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success
Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...
International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation
The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...
Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...
J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products
A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...
Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its...
J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global...
J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC
The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...
AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China
AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China,...
J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients
Johnson & Johnson (J&J; NYSE: JNJ) has released data from a Phase III study showing...